tetano
Editor, Senior Moderator
Vaccine
. 2023 Jan 6;S0264-410X(23)00004-X.
doi: 10.1016/j.vaccine.2023.01.003. Online ahead of print.
CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series
Narges Ebrahimi[SUP] 1 [/SUP], Mahsa Mazdak[SUP] 2 [/SUP], Vahid Shaygannejad[SUP] 3 [/SUP], Omid Mirmosayyeb[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Several reports have been documented in possible association with the administration of different severe acute respiratory coronavirus 2 (SARS-CoV-2) vaccines and central nervous system (CNS)demyelinating disorders, specifically post mRNA vaccines. We report twelve cases of developing Multiple sclerosis (MS) or Neuromyelitis Optica spectrum disorders (NMOSD) following neither the first nor second dose of inactivated or viral vector COVID-19 vaccine.
Methods: We retrospectively compiled twelve patients' medical information with a new onset of MS or NMOSD in their first six weeks following a COVID-19 vaccine.
Results: We report twelve cases of MS (n = 9), clinically isolated syndrome (CIS)(n = 1), and NMOSD (n = 2) following COVID-19 inactivated vaccines (n = 11) or viral vector vaccines (n = 1), within some days following either the first (n = 3), second dose (n = 8), or third dose (n = 1). Their median age was 33.3 years, ranging from 19 to 53 years. Ten were women (83 %). All patients fully (n = 5) or partially (n = 2) recovered after receiving 3 doses of Corticosteroids. Common medications were Natalizumab, Teriflunomide, Dimethyl fumarate, and Rituximab. Also, Interferon beta 1-a was administered to one patient with severe symptoms of numbness.
Conclusion: Our case series identifies the Sinopharm BBIBP-CorV and the AstraZeneca AZD1222 vaccines as potential triggers for CNS demyelinating diseases. Vaccine administration routines are not affected by these rare and coincidental events. However, these manifestations are not deniable and require serious attention. Further investigations are needed to clarify the actual mechanisms and real associations.
Keywords: COVID-19 vaccine; Demyelinating disease; Multiple sclerosis; NMOSD; Neuromyelitis Optica spectrum disorders; Vaccination.
. 2023 Jan 6;S0264-410X(23)00004-X.
doi: 10.1016/j.vaccine.2023.01.003. Online ahead of print.
CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series
Narges Ebrahimi[SUP] 1 [/SUP], Mahsa Mazdak[SUP] 2 [/SUP], Vahid Shaygannejad[SUP] 3 [/SUP], Omid Mirmosayyeb[SUP] 1 [/SUP]
Affiliations
- PMID: 36635139
- DOI: 10.1016/j.vaccine.2023.01.003
Abstract
Background: Several reports have been documented in possible association with the administration of different severe acute respiratory coronavirus 2 (SARS-CoV-2) vaccines and central nervous system (CNS)demyelinating disorders, specifically post mRNA vaccines. We report twelve cases of developing Multiple sclerosis (MS) or Neuromyelitis Optica spectrum disorders (NMOSD) following neither the first nor second dose of inactivated or viral vector COVID-19 vaccine.
Methods: We retrospectively compiled twelve patients' medical information with a new onset of MS or NMOSD in their first six weeks following a COVID-19 vaccine.
Results: We report twelve cases of MS (n = 9), clinically isolated syndrome (CIS)(n = 1), and NMOSD (n = 2) following COVID-19 inactivated vaccines (n = 11) or viral vector vaccines (n = 1), within some days following either the first (n = 3), second dose (n = 8), or third dose (n = 1). Their median age was 33.3 years, ranging from 19 to 53 years. Ten were women (83 %). All patients fully (n = 5) or partially (n = 2) recovered after receiving 3 doses of Corticosteroids. Common medications were Natalizumab, Teriflunomide, Dimethyl fumarate, and Rituximab. Also, Interferon beta 1-a was administered to one patient with severe symptoms of numbness.
Conclusion: Our case series identifies the Sinopharm BBIBP-CorV and the AstraZeneca AZD1222 vaccines as potential triggers for CNS demyelinating diseases. Vaccine administration routines are not affected by these rare and coincidental events. However, these manifestations are not deniable and require serious attention. Further investigations are needed to clarify the actual mechanisms and real associations.
Keywords: COVID-19 vaccine; Demyelinating disease; Multiple sclerosis; NMOSD; Neuromyelitis Optica spectrum disorders; Vaccination.